|
MechanismTau tubulin kinase (TTBK) family inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment - ClinGlio
100 Clinical Results associated with Lipopharma Therapeutics SL
0 Patents (Medical) associated with Lipopharma Therapeutics SL
100 Deals associated with Lipopharma Therapeutics SL
100 Translational Medicine associated with Lipopharma Therapeutics SL